Objective-There are several pathways that mediate the aberrant metabolism of glucose and that might induce greater vascular damage in the setting of diabetes. The polyol pathway mediated by aldose reductase (AR) has been postulated to be one such pathway. However, it has been reported that AR reduces toxic lipid aldehydes and, under some circumstances, might be antiatherogenic. Methods and Results-Atherosclerosis development was quantified in 2 lines of transgenic mice expressing human AR (hAR) crossed on the apolipoprotein E knockout background. The transgenes were used to increase the normally low levels of this enzyme in wild-type mice. Both generalized hAR overexpression and hAR expression via the Tie 2 promoter increased lesion size in streptozotocin diabetic mice. In addition, pharmacological inhibition of AR reduced lesion size.
T he reason diabetes mellitus causes increased cardiovascular disease is unclear. Both type 1 and type 2 diabetes mellitus are associated with multiple metabolic abnormalities, including reduced insulin signaling, dyslipidemia, hyperglycemia, and aberrant glucose metabolism. 1 This latter process has been studied primarily in vitro and is associated with increased production of reactive oxygen species (ROS), DNA strand breaks, and protein glycation. 1 Among the several pathways thought to do this is the polyol pathway. Aldose reductase (AR) converts glucose into sorbitol, which is then metabolized to fructose and trioses. AR may create excess ROS because of altered NADH/NADPH and produce sugars such as fructose that are more likely to create advanced glycation end products (AGEs). AR expression is increased in inflammatory macrophages, and AR enzymatic activity increases production of 4-hydroxynonenal. 2 Both the in vivo actions of AR and its role in atherosclerosis are controversial. On the low-density lipoprotein (LDL) receptor knockout background, generalized overexpression of human AR (hAR) increases atherosclerosis, but only in diabetic mice. 3 These data suggest that hyperglycemia is needed to provide sufficient substrate for the vasculotoxic effects of this enzyme. Mice with a knockout of AR have minimal phenotype; their only obvious alteration is a reduction in renal concentration. 4 However, on the apolipoprotein E knockout (apoEϪ/Ϫ) background AR deficiency has been reported to promote atherosclerosis and increase vascular content of 4-hydroxynonenal, 5 perhaps secondary to reduced oxidation of phospholipids. 6 AR expression and activity vary among species. Ischemia/ reperfusion injury in the rat heart is reduced by AR inhibitors (ARIs). 7 However, mice do not respond in a similar manner unless their relatively low endogenous AR expression is supplemented by a transgene expressing hAR. 3 Transgenic expression of hAR increases mouse macrophage AR expression to levels found in humans. 3 Thus, it is argued that hAR expression in the mouse mimics human biology.
We asked the following questions: Does hAR expression increase atherosclerosis in diabetic apoEϪ/Ϫ mice? If atherosclerosis is increased by AR expression, do ARIs correct this? Does endothelial cell (EC) production of AR alter EC biology and atherosclerosis development? Our results show that the answer to each of these questions is yes.
Methods
All studies were performed with the approval of the institutional animal care and use committee of Columbia University (New York, NY). The animal characterization and study design is listed in the supplemental materials, available online at http://atvb.ahajournals.org. 8, 9 Total cholesterol and triglyceride (TG) levels were determined in fasting mice using commercially available kits (Thermo Electron). Glucose levels were determined from samples of tail vein blood using a glucometer (Abbott Diabetes Care Co.). AR enzymatic activity in aorta was measured as previously described. 3, 10 Atherosclerosis assays were performed at the indicated times of euthanasia. Staining with Sudan IV and Oil Red O, as well as en face lesion area of the aorta (using ImagePro Plus software, version 4.1.0.0, Media Cybernetics) and atherosclerotic lesion area (using a Zeiss microscope and the image analysis system AxioVision 4.5), used published methods 11 and are described in the supplemental materials. Staining and immunofluorescence details for AR and CD31 detection are provided in the supplemental materials.
Endothelial vasorelaxation was studied in 14-week diabetic mice and their citrate controls as described previously. 12, 13 Oxidized human LDL (oxLDL) (Sigma) was prepared and characterized as published in the literature. 14, 15 For cell culture studies, 3 different lines of wild-type (WT) and ARϩ murine aortic ECs were established from 3 individual mouse aortas as described previously. 16 Confluent cells were incubated with either high glucose (HG) (25 mmol/L D-glucose), HG with the ARI zopolrestat (200 mol/L), small interfering RNA against hAR (20 nmol/L), osmotic controls (5.5 mmol/L D-glucose and 19.5 mmol/L D-mannitol), or oxLDL (5 g/mL) or were preincubated with zopolrestat (200 mol/L) for 1 hour followed by incubation with oxLDL for 4 hours. (See supplemental materials for details.)
Detailed methodology of Western blotting and zymography performed on tissue samples and the cell lysates is provided in the supplemental materials.
Statistical Analysis
All data are reported as meanϮSD unless otherwise specified. Data were analyzed by 1-way ANOVA using commercially available software (Statview, version 5.0.1, SAS Institute, Cary, NC). Probability values Յ0.05 were considered statistically significant.
Results

AR Activity and Vascular AR Expression in Mouse Aorta
AR activity was measured in WT and apoEϪ/Ϫ mouse aorta with and without diabetes; it has been reported to increase with diabetes. 17 AR activity was greater in 12-week diabetic apoEϪ/Ϫ mouse aorta, 10.80Ϯ1.80 nmol of NADPH/minute per mg of protein versus 4.30Ϯ1.30 nmol of NADPH/minute per mg of protein in controls. However, AR activity in diabetic apoEϪ/Ϫ mice was lower than that in nondiabetic hAR aorta (16.50Ϯ3.40 nmol NADPH/minute per mg of protein), whereas in diabetic hAR mice, AR activity was more than 2-fold greater (31Ϯ4 nmol of NADPH/minute per mg of protein).
AR expression in the aortic root of nondiabetic and diabetic apoEϪ/Ϫ mice (14 weeks) of age was evident in ECs; it colocalized with CD31 ( Figure 1A ). Some AR expression was also found in other areas of the artery, probably indicative of some macrophage AR expression. 2 Atherosclerotic human carotid artery also revealed colocalization of AR with CD-31 ( Figure 1B ).
Effects of Generalized hAR Expression on Atherosclerosis
Plasma glucose, TG, and total cholesterol levels were higher in diabetic apoEϪ/Ϫ and apoEϪ/ϪhARϩ mice compared with nondiabetic controls (Tables 1 and 2). Several inflam- Figure 1 . A, Immunofluorescence sections of aortic root double-stained with anti-AR IgG (green) and anti-CD31 IgG (red) from 14-week-old nondiabetic and diabetic apoEϪ/Ϫ male mice; merged image is also shown. B, Immunofluorescence sections of aorta from atherosclerotic human carotid artery double-stained with anti-AR IgG (green) and anti-CD-31 (red); merged image is also shown. DM indicates diabetes mellitus. matory markers increased with diabetes (interleukin [IL] 1, IL2, IL6, IL10, IL12, and monocyte chemoattractant protein-1), but hAR expression did not alter these markers. At 14 weeks of duration of diabetes, mean atherosclerotic lesion area at the aortic sinus was 52 486Ϯ3604 m 2 in apoEϪ/Ϫ mice and 79 758.67Ϯ6354.37 m 2 in apoEϪ/ϪhARϩ mice (PϽ0.0001) ( Figure 2A ). Diabetes, as expected, led to greater lesion areas inϮhAR, a result that correspond with greater plasma cholesterol. Sudan IV stain for aortic en face area also showed greater lesion area in diabetic apoEϪ/ϪhARϩ mice compared with diabetic apoEϪ/Ϫ mice ( Figure 2B , PϽ0.05).
Effects of AR Inhibition on Atherosclerosis
If AR activity was a factor in atherosclerosis development, its inhibition should reduce lesions. When apoEϪ/ϪhARϩ were treated with a competitive inhibitor, atherosclerosis decreased Ͼ70% in apoEϪ/ϪhARϩ diabetic mice, from 63 480Ϯ 7580 m 2 to 19 011Ϯ4824 ( Figure 2C ).
hAR Expression Created More Inflammatory-Appearing Lesions
Infiltration of macrophages as detected by CD-68 (Mac-1) staining of the aortic roots was greater in diabetic apoEϪ/Ϫ hARϩ mice than in nondiabetic controls and diabetic apoEϪ/Ϫ mice ( Figure 3A ). Analysis of gross composition of the lipid core did not reveal any significant changes of other cell types.
AR Affects Endothelial Dysfunction and Vascular Inflammation
On exposure of aortic rings to increasing doses of acetylcholine, there was a significant decrease in the endotheliumdependent relaxation in diabetic apoEϪ/ϪhARϩ mice compared with diabetic apoEϪ/Ϫ mice ( Figure 4A ). However, there were no significant changes in the diabetic apoEϪ/Ϫ mice compared with their nondiabetic controls. Sodium nitroprusside-dependent vasorelaxation remained unchanged in all groups (data not shown). Although alterations in plasma lipids, especially TG, are associated with changes in endothelial function, lipid profiles were similar in apoEϪ/Ϫ and apoEϪ/ϪhARϩ mice (Table 1) . ECs isolated from hAR transgenic mice had greater vascular cell adhesion molecule (VCAM)-1 and matrix metalloproteinase (MMP)-2 expression than WT cells treated with HG ( Figure 4B and 4C). Treatment with the ARI zopolrestat decreased VCAM-1 and MMP-2 expression in HG-treated ECs. Similar results were seen in MMP-2 activity ( Figure  4D ). Alternatively silencing of AR using a small interfering RNA against hAR decreased the VCAM-1 ( Figure 4D ) and MMP-2 ( Figure 4E ) expression, complementing the ARI data. On treatment with oxLDL, ECs from AR mice showed increased expression of VCAM-1 and MMP-2 compared with WT control and untreated cells ( Figure 4F and 4G) . ARI treatment significantly decreased VCAM-1 and MMP-2 expression in the cells treated with oxLDL ( Figure 4H and 4I) . MMP-2 activity was also significantly increased in cells treated with oxLDL compared with untreated cells, and the ARI significantly reduced MMP-2 activity in oxLDL-treated cells ( Figure 4G ).
Creation of Tie2-hAR Mice
Markedly different expression patterns in heart, lung, and aorta were found in 3 lines of Tie2-hAR transgenic mice ( Figure 5B ). The line with the greatest aortic expression was studied further. Protein expression of hAR in aorta tissues is shown in Figure 5C . CD31 antibody positive cells from heart isolated by fluorescence-activated cell sorting showed robust hAR gene expression ( Figure 5D ). No expression was found in peritoneal and bone marrow-derived macrophages.
Atherosclerosis in Tie2-hAR/apoE؊/؊ Mice
Plasma cholesterol concentrations in diabetic mice were significantly higher than nondiabetic mice but were similar between the apoEϪ/Ϫ and Tie2-hAR/apoEϪ/Ϫ mice ( Table  2 ). Eight weeks after streptozotocin (STZ) diabetes Tie2-hAR/apoEϪ/Ϫ animals had significantly larger lesions than diabetic apoEϪ/Ϫ mice; en face area increased from 4.0Ϯ0.5% to 6.3Ϯ0.6%, PϽ0.05. (Figure 6A ). Direct visualization of the aortic arch is shown in Figure 6B . Lesion area in the proximal aorta increased from 37 740Ϯ6880 to 68 580Ϯ10 710 m 2 , PϽ0.05 ( Figure 6C ). Thus, EC AR expression increased lesions in the apoEϪ/Ϫ background.
hAR Expression Leads to Altered Vasodilatation
Tie2-hAR/apoEϪ/Ϫ mice had decreased acetylcholinedependent vasorelaxation of the thoracic aorta compared with the apoEϪ/Ϫ mice ( Figure 6D ). Thus, one effect of AR actions is to create endothelial dysfunction.
Discussion
There are a number of pathways leading to aberrant metabolism of glucose that are thought to be pathological. One of these pathways is through the polyol pathway, leading to sorbitol and fructose production. Oxidation of glucose to sorbitol by AR causes oxidative stress because its cofactor NADPH is converted to NADP; this leads to reduced glutathione and increased ROS. 18, 19 We had shown in a previous study that STZ-induced diabetes accelerated atherosclerosis in hAR-expressing mice. Greater atherosclerosis was associated with diminished cellular antioxidant capacity in aorta. 3 In the current study, we show that hAR expression in apoEϪ/Ϫ mice is atherogenic and that expression specifically in ECs also leads to more disease. Moreover, we show that use of a competitive inhibitor of AR that reduces but does not eliminate AR activity also reduces atherosclerosis.
The mechanisms by which AR mediates/accelerates diabetic complications have been studied. AR has been postulated to produce excess ROS. 20 Macrophages from the hAR transgenic mice express higher levels of scavenger receptors and reduced levels of genes that regulate regeneration of glutathione compared with the WT cells. 3 upregulation of AR in human macrophages might be proinflammatory in foam cells. 2 This has been suggested as one of the ways by which AR might amplify effects of hyperlipidemia and diabetes, leading to atherosclerosis. 2 Endothelial dysfunction and upregulation of VCAM-1 are crucial events in atherosclerosis and occur at early stages after lipid infiltration in the vessel. The sites of expression of VCAM-1 are prominent areas of plaque development. 21 In Figure 4 . A, Endothelium-dependent vasorelaxation tested in isolated mouse aortic rings from nondiabetic and diabetic apoEϪ/Ϫ (nϭ4 and 5, respectively), apoEϪ/ϪhARϩ (nϭ4 and 6, respectively) euthanized at 14 weeks of age. Relaxation is reported as percentage of initial phenylephrine precontraction. Comparisons were conducted among groups for each agonist dose. *PϽ0.05, diabetic apoEϪ/ϪhARϩ vs diabetic apoEϪ/Ϫ (doses Ͼ10 to 6 mol/L); **PϽ0.05, nondiabetic apoEϪ/ϪhAR vs diabetic apoEϪ/Ϫ (doses Ͼ10 to 5.5 mol/L). Murine aortic ECs from the indicated mice were subjected to Western blotting for detection of VCAM-1, MMP-2 antigen, and MMP-2 activity. ECs were exposed to high glucoseϮARI zopolrestat or small interfering RNA against hAR for 24 hours. Similarly, cells were incubated with and without zopolrestat along with oxLDL for 4 hours. Western blotting was performed to detect VCAM-1 (B, D, and H) and MMP-2 (C, E, and I) followed by anti-actin IgG. F and G, Zymography for detection of MMP-2 activity was performed. DM indicates diabetic; NDM, nondiabetic; NG, normal glucose; siAR, small interfering RNA against hAR.
oxLDL-induced
this study, we show colocalization of AR with CD-31 by immunohistochemistry in both diabetic apoEϪ/Ϫ mice and also in human atherosclerotic carotid artery. Greater expression of AR led to endothelial dysfunction and increased expression of VCAM-1 and MMP-2. STZ-induced diabetic hAR overexpressing mouse aorta had decreased acetylcholine-mediated endothelial vasorelaxation compared with the WT aorta. EC expression of hAR had the same effect. Interestingly, although there was a significant rise in AR activity in nondiabetic apoEϪ/Ϫ and 14 week diabetic apoEϪ/Ϫ aorta, the activity did not reach the threshold to elicit endothelial dysfunction.
Endothelial function was improved and VCAM-1 and MMP-2 expression reduced by both pharmacological inhibition and targeted silencing of AR in ECs exposed to high glucose and oxLDL. These findings are similar to the improvement in endothelial function observed by blockade of receptor for advanced glycation end products in atherosclerotic apoEϪ/Ϫ mice. 22 Studies in smooth muscle cells incubated with AGE-bovine serum albumin resulted in greater increments of intercellular adhesion molecule-1 and monocyte chemoattractant protein-1, migration, and monocyte adhesion in AR transgenic versus WT cells. 23 These AGE-bovine serum albumin-mediated increases were suppressed either by ARI (zopolrestat) or AR antisense oligonucleotides. 25 Therefore, AR may aggravate AGE-linked receptor for advanced glycation end products activation, and this, in turn, could accelerate atherosclerosis.
Pharmacological studies have suggested that AR may inhibit endothelial-dependent relaxation changes in diabetic vessels. It has been shown that zopolrestat improves abnormal acetylcholine-and adenosine diphosphate-induced relaxation of aortas from diabetic rabbits. 25 Defective endothelium-dependent relaxation to acetylcholine in diabetic rat aortas was corrected by ARI treatment. 26 Impaired endothelium-dependent relaxation in galactosemic rats was also prevented by the ARI ponalrestat. 26 These findings suggest that increased activity of the AR pathway in hyperglycemia is responsible at least in part for the abnormal endotheliumdependent relaxation in diabetic blood vessels. Consistent with these studies, our data highlight the importance of EC AR actions in vascular response.
Johansson et al showed lesional hemorrhage in brachialcephalic arteries from hyperlipidemic type 1 diabetic mice. 27 They attributed the hemorrhage to the hyperlipidemia that accompanies diabetes. On a Tie2-hAR/apoEϪ/Ϫ background with STZ-induced diabetes, we also found hemorrhage within lesions, but at the aortic root (Supplemental Figure I) , documented by appearance and immunohistochemical staining for TER-199, a red blood cell antigen. As in the studies by others, hemorrhage correlated with lesion size and was found in the setting of diabetes.
Although the current studies in apoEϪ/ϪhARϩ mice and prior studies in LDL receptorϪ/Ϫ mice overexpressing hAR 3 show that hAR increases atherosclerosis, contrary findings linking AR with reduced atherosclerosis have been recently reported. 5 Srivastava et al 5 showed increased lesions in AR knockout mice in the apoEϪ/Ϫ background. In contrast and consistent with a proatherogenic action of AR in atherosclerosis, we observed increased AR in human atherosclerotic tissue. Although we observed reduced lesion size and decreased inflammatory marker levels in ARI zopolrestat treated diabetic apoEϪ/ϪhARϩ mice, earlier studies using the ARI lidorestat in hAR-expressing LDL receptorϪ/Ϫ mice did not find reduced lesion size. However, critically, the ARI lidorestat did not increase lesion size. 28 The absence of atheroprotection in AR knockout mice in the apoEϪ/Ϫ background warrants investigation of potential compensation from other genes that may have adversely affected the phenotype. Alternatively, this suggests that a minimal amount of AR activity is necessary for optimal arterial health, whereas greater amounts can be toxic.
Studies in cultured cells and in injured arteries are consistent with a role for the AR pathway in vascular stress. Treatment of cultured human umbilical vein ECs with ARIs sorbinil and tolrestat reduced tumor necrosis factor-␣stimulated activation of nuclear factor-B, phosphorylation and degradation of IB-␣, and the nuclear translocation of nuclear factor-B, in parallel with reduced upregulation of intercellular adhesion molecule-1 and VCAM-1. 29 In other studies, ARIs or antisense oligonucleotides suppressed tumor necrosis factor-␣-mediated activation of nuclear factor-B. 24, 29 AR inhibition also suppressed neointimal production after balloon injury. 23, 29 Gleissner et al 2 reported expression of AR in CD68ϩ cells (monocytes/macrophages) in human atherosclerotic plaque macrophages. 2 This group also found that monocyte-derived macrophages isolated from human blood incubation with oxLDL had increased AR gene expression and activity along with increased ROS. Inhibition of AR in these oxLDL-stimulated cells attenuated ROS generation. Thus, both EC and macrophage AR might be important in vascular pathobiology.
As with all animal studies that attempt to reproduce human disease, interpretation of our data has several limitations. We argue that diabetic studies in hAR-expressing mice recapitulate human biology more closely than studies in non-hAR mice. The rationale for this is that AR activity is very low in mice, and introduction of the hAR transgene increases AR expression in macrophages 3 and hearts 1 to levels that are comparable to those of humans. However, a limitation of our models is that it is unlikely that we have produced human-like levels of AR expression in all cells; some might have higher expression and some lower. A second limitation of our study is the form of diabetes. STZ is an islet cell toxin that leads to insulin deficiency and is therefore a model of type 1 but not type 2 diabetes. Use of the apoEϪ/Ϫ background also has limitations. The lipid levels are higher than most humans, apoE clearly has multiple in vivo functions, and these mice might have other biological alterations. Nonetheless, this animal is one of the standard models for atherosclerosis research. A potential limitation on the use of ARIs is the specificity of these inhibitors for AR versus aldehyde reductases. Published studies have demonstrated that the carboxylic class of ARIs, such as zopolrestat, is 200-fold more selective for AR than for aldehyde reductase. 30 Hence, at the concentrations used in this study, the inhibition of aldehyde Figure 5 . A, The endothelial-specific transgenic construct in which the hAR transgene is located between promoter and enhancer sequences in Tie2 gene. B, Gene expression of hAR was determined by quantitative real-time PCR in different tissues from 3 different lines: 1, 2, and 4 (nϭ3 to 4 mice/group). C, hAR protein expression in aorta from line 4 mice and control mice. D, hAR gene expression in ECs from heart, from line 4, and from control mice (nϭ3/group). ECs from hearts were isolated by immunoreactivity to CD31 using fluorescence-activated cell sorting.
reductase is unlikely to have played any part in the lesion size reduction in diabetic mice.
There are a number of postulated reasons for increased vascular disease in diabetic patients. Aside from effects of reduced insulin actions and greater fatty acid levels, toxic effects of glucose are implicated. For this reason, insulin treatment and better glucose control appear to be beneficial in type 1 diabetes. 31 In type 2 diabetes, the ACCORD trial showed a marked reduction in nonfatal myocardial infarction rate in a better glucose-controlled group of type 2 diabetic patients despite the tendency to greater mortality. 32 There are several pathways leading from glucose to altered cellular/ tissue function. One of these is via AR. The genetic insufficiency of AR in the mouse might be one reason that mice often do not show greater atherosclerosis with diabetes. 33 Humanizing the mouse by transgenic expression of this enzyme may illustrate one route to understanding pathological processes in diabetic humans. 
